By combining glucagon agonism with the powerful appetite suppression and insulin-sensitizing effects of GLP-1/GIP activation, retatrutide produces a uniquely comprehensive metabolic intervention that addresses all three primary drivers of excess weight: excessive appetite, insufficient satiety, and reduced energy expenditure
Ewing Weight Loss Clinic integrates these practices into their Bariatric Program, which includes diet, exercise, and supplements
There are pros and cons to this approach (more on the supply situation down below), but they do make taking the medication rather seamless from the patients perspective
The latter was similar to the benefit seen with the injectable version of semaglutide
Clinical trials demonstrate approximately 15% body weight reduction with semaglutide 2.4 mg weekly
GLP-1 therapies promote satiety and reduce food intake, making them an effective long-term weight management solution when combined with a balanced diet and exercise